Lloyd Mitchell Segal - 12 Jan 2026 Form 4 Insider Report for Aktis Oncology, Inc. (AKTS)

Reporting relationship: Director
Issuer ticker: AKTS
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jan 2026, 17:00:08 UTC
Prior SEC filing: 08 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Karen McCarthy, as Attorney-in-Fact

Key filing fact

Lloyd Mitchell Segal filed Form 4 for Aktis Oncology, Inc. (AKTS) on 12 Jan 2026.

Key facts

This page summarizes Lloyd Mitchell Segal's Form 4 filing for Aktis Oncology, Inc. (AKTS).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Jan 2026, 17:00.

Change

Previous filing in this sequence was filed on 08 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001477123 Primary reporting owner

Segal Lloyd Mitchell

Relationship: Director
Address: C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON
Signature: /s/ Karen McCarthy, as Attorney-in-Fact
Signature date: 12 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKTS transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +19,631
Change %
Price
Shares after: 19,631
Date: 12 Jan 2026
Ownership: See Footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKTS transaction Derivative

Series A Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -50,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Jan 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 13,142
Exercise price
Footnotes: F2, F3

AKTS transaction Derivative

Series B Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -24,687
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Jan 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 6,489
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration.

Footnote F2

Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.

Footnote F3

The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock.